News Quantified

ABBV – abbvie inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

AbbVie (NYSE:ABBV) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.

AbbVie (NYSE:ABBV) was given a new $230.00 price target on by analysts at UBS Group AG.

AbbVie: The Market Is Getting It Wrong [Seeking Alpha]

AbbVie (NYSE:ABBV) had its price target raised by analysts at Morgan Stanley from $269.00 to $270.00. They now have an "overweight" rating on the stock.

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise [Seeking Alpha]

-5.4%

MISS

-4.6%

BEAT

-3.1%

BEAT

1.8%

BEAT

Sanford C. Bernstein

Evercore ISI Group

Form 8-K AbbVie Inc. For: Feb 04

Form 8-K AbbVie Inc. For: Jan 07

Form 4 AbbVie Inc. For: Dec 31 Filed by: RAPP EDWARD J

Form 4 AbbVie Inc. For: Dec 31 Filed by: Quaggin Susan E

Form 4 AbbVie Inc. For: Dec 31 Filed by: Alpern Robert J

Top News Gainers

3/26 Form PX14A6G AbbVie Inc. Filed by: United Church Funds, Inc. 9.7%

3/3 Form 4 AbbVie Inc. For: Feb 28 Filed by: Schumacher Laura J 4.8%

3/19 Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)] 4.7%

2/7 Q4/2019 12/31/2019 EPS 2.210 ZacksConsensus 2.200 ActVsEst 0.010 - Beat 4.6%

3/23 Abbvie: Buy The Coronavirus Dip For These 3 Reasons [Seeking Alpha] 4.5%

6/27 AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered [Seeking Alpha] 3.7%

6/25 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript) [Seeking Alpha] 3.6%

11/8 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia 3.6%

8/16 Form 4 AbbVie Inc. For: Aug 14 Filed by: Gosebruch Henry O 3.3%

6/26 AbbVie Inc (NYSE: ABBV) had its "hold" rating re-affirmed by analysts at Citigroup Inc. 3.2%

Top News Decliners

6/25 AbbVie nears deal to buy Allergan for more than $60 bln - WSJ [Reuters] -11.8%

3/20 Form 4 AbbVie Inc. For: Mar 18 Filed by: Durkin Brian L -6.5%

3/12 AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia -4.1%

2/24 Form 4 AbbVie Inc. For: Feb 20 Filed by: Durkin Brian L -3.9%

10/1 Lanny's October Dividend Stock Watch List [Seeking Alpha] -3.6%

3/10 Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha] -3.0%

2/27 AbbVie Inc (NYSE: ABBV) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -2.9%

3/17 AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction -2.7%

4/7 Form PX14A6G AbbVie Inc. Filed by: ZEVIN ASSET MANAGEMENT LLC -2.6%

2/12 Results from Chinese drug trials for coronavirus due in weeks: expert [Reuters (UK)] -2.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day